Dr. Morris Rosenberg

Scientific Advisory Board Member

Dr. Morris Rosenberg, D.Sc., is a biotechnology veteran with over 30 years of experience in developing therapeutic agents for various diseases. He has contributed to the development of several commercially approved therapeutics, including Adcetris™, Avonex™, Angiomax™, Forteo™, and Trodelvy™. A native of St. Louis, Missouri, he earned a B.S. in Biology (1982) and a B.S. (1982), M.S. (1985), and D.Sc. (1989) in Chemical Engineering from Washington University in St. Louis.

Dr. Rosenberg began his career at Invitron (1987-1990), where he developed large-scale cell culture production processes for murine and chimeric antibodies. He then worked at Biogen (1990-1998) in Process Sciences and later joined Eli Lilly as Director of Biologics Process Development (1998-2001). In 2001, Dr. Rosenberg joined Seattle Genetics, where he played a key role in building the company’s antibody-drug conjugate platform for cancer treatment, serving as VP, SVP, and EVP of Development and Manufacturing until 2012. He later became the Chief Technical Officer of Immunomedics, helping launch Trodelvy™ for the treatment of third-line Triple Negative Breast Cancer.

In 2024 Dr. Rosenberg was awarded the Lifetime Achievement Award in the ADC field by the sponsors of the World ADC Conference.

Dr. Rosenberg is currently the founder and CEO of MRBC LLC, a consulting firm with 20 members providing services to the biotech industry.